Aspect Partners’s Roivant Sciences ROIV Stock Holding History

Aspect Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.08K	Hold	200	–	–	﹤0.01%	356
2026 Q1	$5.54K	Hold	200	–	–	﹤0.01%	348
2025 Q4	$4.34K	Buy	+200	New	+$3.95K	﹤0.01%	404

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Aspect Partners's ROIV Position: Q2 2026 in Review

Aspect Partners held its Roivant Sciences (ROIV) position steady in Q2 2026 at 200 shares worth $7.08K. The position accounts for ﹤0.01% of the portfolio, ranked #356.

Aspect Partners first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Aspect Partners held 200 shares of Roivant Sciences worth $7.08K as of Q2 2026.
Aspect Partners left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #356 holding.
Aspect Partners first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.